Literature DB >> 1686301

Behavioral and receptor binding analysis of the alpha 2-adrenergic agonist, 5-bromo-6 [2-imidazoline-2-yl amino] quinoxaline (UK-14304): evidence for cognitive enhancement at an alpha 2-adrenoceptor subtype.

A F Arnsten1, F M Leslie.   

Abstract

The ability of the alpha 2-agonists clonidine, B-HT920 (6-allyl-2-amino-5,6,7,8-tetrohydro-4H-thiazolo-[4,5-d]-azepine) and guanfacine to improve memory in aged monkeys has been related to their affinity to bind at a proposed rauwolscine-insensitive (Ri) subtype of alpha 2-adrenergic receptor, while their hypotensive and sedating effects have been related to affinity at a rauwolscine-sensitive site (Rs) (Arnsten et al., 1988). The present study examined the alpha 2-agonist UK-14304 (5-bromo-6 [2-imidazoline-2-yl amino] quinoxaline) for its binding characteristics in tissue from the brain of the rat and for its behavioral effects in aged monkeys. The drug UK-14304 was found to have slightly higher affinity for the Ri than the Rs site (Ki values of 138 and 245 nM, respectively), but was not as selective as the alpha 2-agonist guanfacine (Ki values of 23 and 340 nM, respectively). Consistent with this binding profile, very small doses of UK-14304 (0.00017-0.17 micrograms/kg) produced a reliable but modest improvement in memory in the aged monkeys (average improvement of 16.7% +/- 2.6% following an optimal dose). No hypotensive or sedating side effects were observed at these small doses. However, hypotension and sedation emerged rapidly when the dose was raised above 1.7 micrograms/kg and at the largest doses tested (50.0-100.0 micrograms/kg), hypotension was severe (systolic pressure below 70 mm Hg) and the animals were too sedated to complete cognitive testing. The separation between doses that improved memory and those that produced hypotension and sedation was not as great for UK-14304 as it was for guanfacine, consistent with the greater selectivity of guanfacine for the Ri site. These results offer a fourth example whereby the ability of an alpha 2-agonist to improve cognitive function, without side effects, could be related to the relative affinities for the Ri and Rs sites.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1686301     DOI: 10.1016/0028-3908(91)90024-6

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  9 in total

1.  Alpha-2 adrenergic agonists decrease distractibility in aged monkeys performing the delayed response task.

Authors:  A F Arnsten; T A Contant
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

2.  Mutation of the alpha2A-adrenoceptor impairs working memory performance and annuls cognitive enhancement by guanfacine.

Authors:  Jenna S Franowicz; Lynn E Kessler; Catherine M Dailey Borja; Brian K Kobilka; Lee E Limbird; Amy F T Arnsten
Journal:  J Neurosci       Date:  2002-10-01       Impact factor: 6.167

3.  Clonidine and guanfacine attenuate phencyclidine-induced dopamine overflow in rat prefrontal cortex: mediating influence of the alpha-2A adrenoceptor subtype.

Authors:  J David Jentsch; Diana Sanchez; John D Elsworth; Robert H Roth
Journal:  Brain Res       Date:  2008-10-18       Impact factor: 3.252

Review 4.  The Role of the Noradrenergic System in Autism Spectrum Disorders, Implications for Treatment.

Authors:  David Q Beversdorf
Journal:  Semin Pediatr Neurol       Date:  2020-06-24       Impact factor: 1.636

5.  Alpha 2-adrenoceptor antagonists potentiate acetylcholinesterase inhibitor effects on passive avoidance learning in the rat.

Authors:  F Camacho; C P Smith; H M Vargas; J T Winslow
Journal:  Psychopharmacology (Berl)       Date:  1996-04       Impact factor: 4.530

Review 6.  Clinical trials: new opportunities.

Authors:  Sandra Bond Chapman; Carl W Cotman; Howard M Fillit; Michela Gallagher; Christopher H van Dyck
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2012-05-08       Impact factor: 6.053

7.  Effects of alpha 2-adrenoceptor agonists dexmedetomidine and guanfacine on morphine analgesia and tolerance in rats.

Authors:  Sinan Gursoy; Ercan Ozdemir; Ihsan Bagcivan; Ahmet Altun; Nedim Durmus
Journal:  Ups J Med Sci       Date:  2011-09-16       Impact factor: 2.384

8.  Guanfacine's mechanism of action in treating prefrontal cortical disorders: Successful translation across species.

Authors:  Amy F T Arnsten
Journal:  Neurobiol Learn Mem       Date:  2020-10-17       Impact factor: 2.877

9.  Pharmacological and therapeutic directions in ADHD: Specificity in the PFC.

Authors:  Florence Levy
Journal:  Behav Brain Funct       Date:  2008-02-28       Impact factor: 3.759

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.